Aclaris Therapeutics, Inc. (ACRS) Operating cash flow 2016–2025
Aclaris Therapeutics, Inc. (ACRS) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$47.1MFY2025 · since FY2016: -$34.6M → -$47.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$47.1M | -134.7% |
| FY2024 | -$20.1M | +74.4% |
| FY2023 | -$78.3M | -15.9% |
| FY2022 | -$67.6M | -29.6% |
| FY2021 | -$52.1M | -34.9% |
| FY2020 | -$38.6M | +59.9% |
| FY2019 | -$96.4M | +4.3% |
| FY2018 | -$100.8M | -84.4% |
| FY2017 | -$54.7M | -58.0% |
| FY2016 | -$34.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ACRS financial trends
ACRS RevenueACRS Net incomeACRS Net marginACRS Gross profitACRS Gross marginACRS Operating incomeACRS Operating marginACRS Free cash flowACRS Capital expendituresACRS Return on equityACRS Stock buybacksACRS Dividends paidACRS Total assetsACRS Total liabilitiesACRS Shareholders’ equityACRS overview →